Free Trial

Stryker (SYK) Stock Forecast & Price Target

Stryker logo
$378.70 +1.87 (+0.50%)
Closing price 09/22/2025 03:59 PM Eastern
Extended Trading
$378.60 -0.10 (-0.03%)
As of 07:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
6
Buy
14

Based on 20 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 6 have given a hold rating, and 14 have given a buy rating for SYK.

Consensus Price Target

$430.33
13.63% Upside
According to the 20 analysts' twelve-month price targets for Stryker, the average price target is $430.33. The highest price target for SYK is $456.00, while the lowest price target for SYK is $370.00. The average price target represents a forecasted upside of 13.63% from the current price of $378.70.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYK Analyst Ratings Over Time

TypeCurrent Forecast
9/23/24 to 9/23/25
1 Month Ago
8/24/24 to 8/24/25
3 Months Ago
6/25/24 to 6/25/25
1 Year Ago
9/24/23 to 9/23/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
15 Buy rating(s)
15 Buy rating(s)
15 Buy rating(s)
Hold
6 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$430.33$430.10$427.30$378.58
Forecasted Upside13.63% Upside9.22% Upside8.91% Upside3.29% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Stryker Stock vs. The Competition

TypeStrykerMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside13.63% Upside1,650.87% Upside11.33% Upside
News Sentiment Rating
Positive News

See Recent SYK News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/18/2025Redburn Partners
3 of 5 stars
 Set Target$420.00+11.54%
9/18/2025Rothschild Redb
0 of 5 stars
 UpgradeHold
9/18/2025Rothschild & Co Redburn
0 of 5 stars
Ed Ridley-Day
Not Rated
Initiated CoverageNeutral$420.00+11.53%
8/4/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetHold$410.00 ➝ $415.00+8.79%
8/1/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$435.00 ➝ $445.00+17.27%
8/1/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$442.00 ➝ $448.00+13.89%
7/14/2025BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$390.00 ➝ $415.00+5.80%
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$443.00 ➝ $455.00+20.09%
5/5/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$450.00+17.24%
5/5/2025JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
5/2/2025Roth Mkm
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$405.00 ➝ $456.00+20.75%
3/4/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set Target$422.00+12.41%
2/10/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$418.00 ➝ $443.00+13.18%
2/3/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$450.00+17.62%
1/29/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$425.00 ➝ $435.00+11.57%
1/29/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$420.00 ➝ $445.00+12.68%
1/29/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$400.00 ➝ $440.00+11.41%
1/29/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$420.00 ➝ $435.00+10.15%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeEqual WeightOverweight$370.00 ➝ $445.00+13.48%
10/30/2024Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight$380.00 ➝ $420.00+17.04%
10/30/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetNeutral$366.00 ➝ $370.00+2.61%
10/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$378.00 ➝ $405.00+12.73%
9/10/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$405.00+11.64%
4/11/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$365.00 ➝ $400.00+15.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:28 AM ET.


Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 22, 2025. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Stryker Co.:

  • The current stock price is around $387, reflecting a strong market position in the medical technology sector.
  • The company reported a significant increase in quarterly revenue, up 11.1% year-over-year, indicating robust growth and demand for its products.
  • Stryker Co. has a solid return on equity of 23.94%, showcasing effective management and profitability relative to shareholder equity.
  • The firm has a manageable debt-to-equity ratio of 0.70, suggesting a balanced approach to leveraging debt for growth while maintaining financial stability.
  • With a quarterly dividend of $0.84 per share and a yield of 0.9%, investors can benefit from regular income in addition to potential capital appreciation.

Stryker
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Stryker Co. for these reasons:

  • The stock has a high P/E ratio of 49.88, which may indicate that it is overvalued compared to its earnings, potentially leading to price corrections.
  • With a beta of 0.93, the stock is less volatile than the market, which may limit potential high returns during bullish market conditions.
  • The dividend payout ratio is currently at 44.50%, which, while sustainable, may limit the company's ability to reinvest profits into growth opportunities.
  • Market analysts have set a modest earnings per share guidance for FY 2025, which may not excite growth-focused investors looking for aggressive expansion.
  • The stock has a 52-week high of $406.19, suggesting it may face resistance at higher price levels, making it a less attractive buy at current prices.

SYK Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $430.33, with a high forecast of $456.00 and a low forecast of $370.00.

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last twelve months. There are currently 6 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SYK shares.

According to analysts, Stryker's stock has a predicted upside of 13.63% based on their 12-month stock forecasts.

Over the previous 90 days, Stryker's stock had 1 upgrade by analysts.

Analysts like Stryker less than other "medical" companies. The consensus rating score for Stryker is 2.70 while the average consensus rating score for "medical" companies is 2.78. Learn more on how SYK compares to other companies.


This page (NYSE:SYK) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners